Influenza A virus nucleoprotein mRNA (NP mRNA)

The Influenza A virus nucleoprotein (NP) mRNA is the transcript produced from the fifth segment of the viral genome, serving as the essential template for the synthesis of the nucleoprotein. NP is a multifunctional structural protein that encapsidates the viral RNA to form ribonucleoprotein (RNP) complexes, which are mandatory for viral transcription, replication, and assembly (Source: UniProt P03466). Because the NP gene sequence is highly conserved across various influenza A subtypes, its mRNA is considered a high-value target for broad-spectrum antiviral therapies (Source: PubMed PMID 12796516). Therapeutic strategies such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are designed to bind specifically to the NP mRNA, leading to its degradation or blocking its translation into protein. Experimental studies have demonstrated that silencing NP mRNA can significantly inhibit viral replication and reduce viral titers in preclinical models (Source: PubMed PMID 15308119). While no mRNA-targeting drugs for influenza are currently FDA-approved, research continues into optimizing delivery systems like lipid nanoparticles to improve efficacy and safety in human patients.

Other names

Influenza A virus NP gene mRNAInfluenza A virus segment 5 mRNANP gene transcriptNucleocapsid protein mRNA

Sequence-specific degradation of viral mRNA via RNA interference (RNAi) or steric hindrance of translation using antisense oligonucleotides (ASOs) to prevent the synthesis of the nucleoprotein.